Journal article

Soluble lymphotoxin is an important effector molecule in GVHD and GVL

Kate A Markey, Angela C Burman, Tatjana Banovic, Rachel D Kuns, Neil C Raffelt, Vanessa Rowe, Stuart D Olver, Alistair LJ Don, Edward S Morris, Allison R Pettit, Yana A Wilson, Renee J Robb, Louise M Randall, Heinrich Korner, Christian R Engwerda, Andrew D Clouston, Kelli PA MacDonald, Geoffrey R Hill

BLOOD | AMER SOC HEMATOLOGY | Published : 2010

Abstract

Tumor necrosis factor (TNF) is a key cytokine in the effector phase of graft-versus-host disease (GVHD) after bone marrow transplantation, and TNF inhibitors have shown efficacy in clinical and experimental GVHD. TNF signals through the TNF receptors (TNFR), which also bind soluble lymphotoxin (LTalpha3), a TNF family member with a previously unexamined role in GVHD pathogenesis. We have used preclinical models to investigate the role of LT in GVHD. We confirm that grafts deficient in LTalpha have an attenuated capacity to induce GVHD equal to that seen when grafts lack TNF. This is not associated with other defects in cytokine production or T-cell function, suggesting that LTalpha3 exerts i..

View full abstract

University of Melbourne Researchers